Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors.

ABSTRACT:

Background

Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (TSC) tumors derived from Sertoli cells or Leydig cells often fail to respond to chemotherapy or radiation therapy and have a 5-year overall survival significantly lower than the more common and more treatable germ line testicular tumors.

Methods

To improve outcomes for TSC cancer, we have developed a therapeutic vaccine targeting inhibin-α, a protein produced by normal Sertoli and Leydig cells of the testes and expressed in the majority of TSC tumors.

Results

We found that vaccination against recombinant mouse inhibin-α provides protection and therapy a

SUBMITTER: Aguilar R 

PROVIDER: S-EPMC5394616 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature